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Abstract
Background: Some individuals control HIV replication without antiretroviral (ARV) therapy.
Objective: To analyze viral suppression in young women in rural South Africa enrolled in a trial 
evaluating a behavioral intervention for HIV prevention.
Methods: Plasma samples were obtained from women ages 13–24 (81 infected at enrollment, 
164 seroconverters). ARV testing was performed using an assay that detects 20 ARV drugs. 
Women were classified as viremic controllers if they were virally suppressed for ≥12 months with 
no ARV drug use.
Results: Samples from 216/245 (88.2%) women had no ARV drugs detected at their first HIV-
positive visit. Thirty-four (15.7%) of the 216 women had a viral load <2,000 copies/mL. Fifteen of 
the 34 women were followed for ≥12 months; 12 were virally suppressed with no ARV drugs 
detected during follow-up. These women were classified as viremic controllers (overall: 
12/216=5.6%). The median CD4 cell count at the first HIV-positive visit was higher among the 12 
controllers than among the 204 women who were not using ARV drugs (759 vs. 549 cells/mm3, 
p=0.02). Some women had a viral load <40 copies/mL at a single study visit, but none were 
classified as elite controllers (viral load <40 copies/mL for ≥12 months with no ARV drug use).
Conclusions: In this cohort, 5.6% of women who were not using ARV drugs had sustained viral 
suppression. This represents a minimum estimate of the frequency of viremic controllers in this 
cohort, since some women were not followed long enough to meet the criteria for classification.
Keywords
HIV; viremic controllers; natural control; young women; South Africa
Introduction
Some HIV-infected individuals are able to maintain low or undetectable levels of HIV RNA 
without antiretroviral therapy (ART).1–3 These individuals often have low levels of viremia 
during acute infection, normal or slightly higher CD4 cell counts, normal levels of immune 
activity, and slower progression to AIDS.4–6 The criteria used to classify these individuals as 
elite or viremic controllers vary, but are usually based on the degree of viral suppression and 
the duration of viremic control in the absence of ART.7,8
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Several factors have been associated with natural control of HIV infection.3,9,10 The ability 
to control viral replication to very low levels may reflect differences in viral genetics, host 
genetics, or innate, humoral, or adaptive immune responses.3,9,10 Most reports have not 
found an association between natural control of HIV infection and race, gender, age, or route 
of HIV acquisition.1,10
Most studies of HIV controllers rely on self-report or medical records to identify individuals 
who are not using antiretroviral (ARV) drugs.11–13 However, previous studies in both HIV-
infected and HIV–uninfected cohorts have demonstrated that self-report of ARV drug use 
may be unreliable.14,15 We developed a high-throughput assay that detects 20 ARV drugs in 
five drug classes. This assay provides an objective method for assessing ARV drug use. In 
this report, we used the multi-drug assay to identify HIV controllers in a cohort of young 
women enrolled in a clinical trial (HIV Prevention Trials Network [HPTN] 068) in rural 
South Africa that evaluated a behavioral intervention for HIV prevention.16,17 HIV viral load 
is associated with HIV transmission risk and HIV treatment outcomes. Information on 
viremic control of HIV infection may help inform the design and interpretation of HIV 
treatment and prevention studies and may also be helpful for understanding the dynamics of 
the HIV epidemic in some populations.
Methods
Study cohort
Samples were obtained from women aged 13–24 who were enrolled in the HPTN 068 study 
(2011–2015).16,17 HPTN 068 evaluated whether a cash transfer conditional on school 
attendance reduced HIV incidence.16,17 Participants were followed until their expected 
school graduation date or study completion. A subset of participants had a single follow-up 
visit 1–2 years after their expected study exit (post-intervention follow-up study). At the 
time when HPTN 068 study was conducted, ART was recommended in the study region for 
individuals with CD4 cell counts ≤200 cells/mm3; earlier ART initiation was recommended 
for pregnant women and those with tuberculosis (CD4 cell count ≤350 cells/mm3).18
Laboratory testing
HIV testing was performed at enrollment (all participants) and at annual follow-up visits for 
participants who were HIV uninfected at enrollment. CD4 cell count testing was performed 
at study sites for HIV-infected participants at their first HIV-positive visit and follow-up 
visits.16 Other laboratory testing described in this report was performed retrospectively at 
the HPTN Laboratory Center (Johns Hopkins University School of Medicine, Baltimore, 
MD, USA). HIV testing was performed to confirm results from site testing and to confirm 
HIV seroconversion events.17 HIV viral load testing was performed using the FDA-cleared 
RealTime HIV-1 Viral Load assay (Abbott Molecular, Abbott Park, IL; limit of 
quantification: 40 copies/mL). Rigorous procedures for sample collection, processing, 
storage, shipping, and testing were used throughout the HPTN 068 trial and in this study, to 
minimize any risk of sample degradation. ARV drug testing was performed using a 
qualitative multi-drug assay based on high-performance liquid chromatography coupled with 
high-resolution accurate mass mass spectrometry.19,20 HIV genotyping was performed using 
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the ViroSeq HIV-1 Genotyping System v2.8 (Abbott Molecular, Des Plaines, IL). HIV 
sequences generated with the ViroSeq system were used for HIV subtyping using the REGA 
HIV-1 Subtyping tool.21 Sequences were submitted to GenBank (Accession numbers: 
KY883695–KY883762, KY888784–KY888875, KY921717–KY921757).
Statistical analysis
HIV controllers were defined as having a viral load below a fixed cutoff (<40 copies/mL for 
elite controllers; <2,000 copies/mL for viremic controllers) at their first HIV-positive visit 
and one or more annual study visits (i.e., for at least 12 months), with no ARV drugs 
detected at those visits. Those who had a single viral load measurement ≥2,000 copies/mL 
during follow-up were included in this group. The viral load cutoffs used to define elite and 
viremic controllers in this report are used by International HIV Controller Consortium 
(www.hivcontrollers.org) and have been used in other reports.22–24 Statistical analysis was 
performed using the SAS software (SAS 9.4). Associations between viremic controllers and 
participant characteristics were examined using Wilcoxon rank sum tests.
Ethical considerations
Study participants and their parents/guardians provided written consent for participation in 
the HPTN 068 study. Written assent was obtained for participants younger than 18 years. 
The HPTN 068 study was approved by ethical review boards at participating institutions.
Results
The HPTN 068 cohort included 245 HIV-infected women; 81 were HIV-infected at 
enrollment and 164 acquired HIV infection during the study (seroconverters, Figure). ARV 
testing was performed using samples collected at the first HIV-positive visit; results were 
obtained for 242 of the 245 HIV-infected women. ARV drugs were detected in samples from 
26 (10.7%) of the 242 women (10 infected at enrollment; 16 seroconverters, Figure). The 26 
women with ARV drugs detected and the three women without ARV drug testing results 
were excluded from further analysis. Thirty-four (15.7%) of the remaining 216 women had a 
viral load <2,000 copies/mL at their first HIV-positive visit (12 infected at enrollment; 22 
seroconverters); three of the 34 women had a viral load <40 copies/mL. The median viral 
load among the 34 women was 492 copies/mL (range: <40–1,479).
Fifteen (44.1%) of the 34 women who had an initial viral load <2,000 copies/mL were 
followed for at least 12 months (median follow-up period: 23 months, range: 13–51 months). 
Twelve of 15 participants had sustained viral suppression (viral load <2,000 copies/mL for at 
least 12 months; median follow-up: 20 months, range 13–42; one of the 12 women had a 
single elevated viral load result of 2,693 copies/mL during this period; Supplemental 
Figure). None of the 12 women had a sustained viral load <40 copies/mL (i.e., no elite 
controllers were identified in this study). ARV drugs were not detected in samples from any 
of the 12 women at any follow-up visit. These 12 women were classified as viremic 
controllers.
Age, viral load, and CD4 cell count were compared for the 12 viremic controllers and the 
other 204 women who had no ARV drugs detected at their first HIV-positive visit (control 
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group). The median age at the first HIV-positive visit was lower for the viremic controllers 
(17.5 years [range: 16–19] vs. 19 years [range: 13–24], p=0.04, Table). This most likely 
reflects selection bias, since the viremic controller group only included women with at least 
12 months of follow-up; women with <12 months follow-up who were enrolled in HPTN 
068 acquired HIV infection in the year before their last study visit. The median viral load at 
the first HIV-positive visit was lower for the viremic controllers than the control group, as 
expected (1,063 copies/mL [range: 61–1,479] vs.17,911 copies/mL [range: <40–5,667,096]). 
The median CD4 cell count at the first HIV-positive visit was higher for the viremic 
controllers than the control group (759 cells/mm3 [range: 448–1,817] vs. 549 cells/mm3 
[range: 13–1,440], p=0.02), and remained above 500 cells/mm3 in seven of the 12 viremic 
controllers throughout the follow-up period (Supplemental Figure). There was no significant 
difference between the median CD4 cell count during the follow-up period among viremic 
controllers and the control group (542 cells/mm3 vs. 538 cells/mm3, respectively, p=0.42).
HIV genotyping was performed for 212 (92.3%) of the 245 HIV-positive women; 33 
samples were not tested (viral load <400 copies/mL or no sample available for testing). 
Results were obtained for 201 (96.7%) of the 212 samples (11 samples failed testing). HIV 
genotyping results from the full HPTN 068 cohort are presented in a separate report.25 HIV 
drug resistance results were obtained for five viremic controllers; (Y181C) was detected in 
only one of these cases. HIV subtyping was performed previously using pol region 
sequences obtained from HIV genotyping. Two-hundred women had subtype C infection, 
including five of 12 viremic controllers; one woman had subtype A infection; the other 
seven viremic controllers did not have genotyping results (most due to low viral load).26
Discussion
This report analyzed viral suppression in young women in rural South Africa. In this cohort, 
216 (88.2%) of the 245 HIV-infected women were not taking ARV drugs at their first HIV-
positive visit (enrollment or seroconversion). Some women had a viral load <40 copies/mL 
at a single study visit, but none met the criteria for elite controllers. Twelve (5.6%) of the 
216 women had sustained viral suppression in the absence of ARV drug use and were 
classified as viremic controllers. This provides a minimum estimate of the frequency of 
viremic controllers in this cohort, because more than half of the 34 women who had an 
initial low viral load value and were not taking ARV drugs were not classified as viremic 
controllers because they were followed for <12 months. Based on results obtained for the 
women with ≥12 months follow-up, we estimate that the true frequency of viremic 
controllers in this cohort is 12.6% ([34 women with initial viral suppression] × [80% 
sustained viral suppression] × [100] / 216 women with no ARV drugs detected). A previous 
study from South Africa reported a high prevalence (17.2%) of individuals who had viral 
loads <50 copies/mL in the absence of ART.27 In other studies, the portion of individuals 
with natural control of HIV infection ranged from <1% to 7.7%.2,3,8,11–13,22,28,29 These 
studies used different criteria to define HIV controllers. Two of these studies used the same 
viral load cutoff to define viremic controllers that was used in this report (2,000 copies/mL); 
those studies reported a prevalence of viremic controllers of 2.7%22 and 3.34%.2 ARV drug 
use was identified in some studies based on self-report or medical records;11–13 some studies 
did not indicate how ARV drug use was assessed.2,3,8,28,29 Our previous studies of men who 
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have sex with men,14,30,31 heterosexual couples,32 and women at high risk of HIV infection,
15 demonstrate that some individuals may not disclose ARV drug use. Therefore, the 
frequency of HIV controllers may be lower than reported in studies that rely on self-report to 
assess ARV drug use.
Higher CD4 cell counts have been observed in HIV controllers in other studies.3,8,33 In this 
report, among women who were not taking ARV drugs, the median CD4 cell count was 
significantly higher among the viremic controllers compared to women with higher viral 
loads. However, we did not observe a significant difference in CD4 cell counts between 
these groups over time. Previous studies have showed an association of natural control of 
HIV infection with specific HLA class I alleles.3,9,10 However, the frequency of these alleles 
in HIV controllers varies from 15% to 86% in different populations,1,3,34 and some of the 
putatively “protective” HLA class I alleles were also identified in HIV progressors who were 
not virally suppressed.34 Therefore, it seems unlikely that HLA class I genotype alone leads 
to natural control of infection. Viral (HIV) genetics may also play a role in natural control of 
HIV infection.
Some HIV drug resistance mutations that have been associated with lower viral fitness (e.g., 
M184I/V)10,35 have been identified in some HIV controllers. In other cases, HIV controllers 
were infected with high-fitness viruses,9,36 that did not have mutations considered to be 
protective genetic factors.35,37 M184I/V was not detected in this study in the five viremic 
controllers who had HIV genotyping results. One viremic controller had HIV with the 
Y181C mutation; this mutation has a minimal impact on HIV replication capacity38 and has 
not been associated with lower viral load levels.35 Because drug resistance data were only 
obtained for five viremic controllers in the HPTN 068 study, we were not able evaluate 
whether drug resistance played a role in viremic control in this cohort. The HPTN 068 study 
did not obtain consent to perform host genetic testing, and phenotypic studies of HIV 
replication capacity could not be performed in this study because insufficient plasma was 
available for analysis.
Most prior reports have found no association of viremic control with gender, age, or race,1,10 
though these associations have been reported in some studies.11 In our study, there was no 
age difference between women who had viral loads <2,000 copies/mL vs. >2,000 copies/mL 
at their first HIV-positive visit. Our finding that the median age of viremic controllers was 
lower than other women (p=0.04) most likely reflects the requirement for a 12-month 
follow-up for classification of viremic control. Women with longer follow-up after their first 
HIV-positive visit were more likely to have enrolled in the HPTN 068 study during an earlier 
school grade, when they were younger.
Previous studies found an association of disease progression with HIV subtype.39 For 
example, HIV subtype D infection has been associated with faster CD4 cell decline, frequent 
virologic rebound during ART, and higher rate of mortality compared to subtypes A, B and 
C.39,40 In one cohort, slower disease progression was observed in women with HIV subtype 
C infection compared to those with subtype A and D infection.41 HIV subtype was 
determined for the majority (82%) of the HIV-infected women in HPTN 068; all but one had 
subtype C infection, including all of the viremic controllers who had genotyping results.
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One potential limitation of this report is that it included both women who were infected at 
study entry and those who acquired HIV infection during the study. Several factors make it 
less likely that were significant differences between the two study groups that might impact 
viremic control. HIV seroconverters were identified at annual study visits; therefore, these 
women were infected in the year prior to the seroconversion visit. Because the study 
enrolled women as young as 13 years of age, some women who were HIV infected at study 
entry were also likely to have been recently infected. The enrollment criteria for HPTN 068 
were also not likely to have impacted enrollment of viremic controllers vs. non-controllers. 
There was no incentive for enrollment of HIV-uninfected women, and no cap or other 
disincentive for enrollment of those with known HIV infection or a history of ARV drug 
exposure. Overall, only 2% of young women and 5% of parent/guardians refused 
participation in the trial,16 and the baseline prevalence of HIV infection in HPTN 068 was 
3.2%, which is similar to the prevalence of HIV in another study performed in population of 
school students in rural South Africa in the same age category (3.8%).42
In conclusion, in this cohort of young women from rural South Africa, we identified a high 
portion of women who were virally suppressed in the absence of ARV drug use (N=34, 
15.7%). Approximately one-third of these women had sustained viral suppression with no 
ARV drug use. The actual frequency of viremic controllers in this cohort may have been 
higher, since HIV infection in some women could not be fully characterized due to limited 
study follow-up. Based on results from women who were followed for at least one year, the 
prevalence of viremic controllers in this cohort was 12.6%. The relatively high frequency of 
viremic controllers in this population suggests that ARV drug testing may be useful in 
addition to HIV viral load testing for evaluating treatment outcomes in future studies, to 
distinguish between those with natural vs. ARV-induced viral suppression. This information 
may also be useful for studies of HIV transmission and dynamics among young women in 
similar settings, since viremic controllers are less likely to transmit HIV to others.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure. Study cohort and identification of viremic controllers in the HPTN 068 cohort.
The figure shows the number of HPTN 068 participants who were HIV-infected at study 
enrollment and the number of women who acquired HIV infection during study follow-up 
(F/U). For each group, the figure shows the number of those participants who had no 
antiretroviral (ARV) drugs detected at their first HIV-positive visit (enrollment or 
seroconversion), the number of participants with viral load levels <2,000 copies/mL at their 
first HIV-positive visit, the number of participants with at least 12 months of follow-up, and 
the number identified as viremic controllers. Loss of virologic control was defined as having 
two or more HIV RNA measurements >2,000 copies/mL during study follow-up.
Abbreviations: mo.: month; F/U: follow-up.
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